These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. Cytomegalovirus infection-enhanced chronic rejection in the rat is prevented by antiviral prophylaxis. Tikkanen J; Kallio E; Pulkkinen V; Bruggeman C; Koskinen P; Lemström K Transplant Proc; 2001; 33(1-2):1801. PubMed ID: 11267518 [No Abstract] [Full Text] [Related]
51. CMV prophylaxis: what is valid in 2002? Heemann U; Wenzel RR Nephrol Dial Transplant; 2002 Apr; 17(4):556-9. PubMed ID: 11917045 [No Abstract] [Full Text] [Related]
52. IGIV prophylaxis therapy for CMV in renal transplant recipients. Mendoza M ANNA J; 1993 Dec; 20(6):691-2. PubMed ID: 8267416 [No Abstract] [Full Text] [Related]
55. Quo vadis? The clinical dilemma of simultaneous cytomegalovirus infection and steroid-resistant rejection. van den Berg AP; Tegzess AM; Scholten-Sampson A; van der Giessen M; The TH; van Son WJ Transplantation; 1991 Dec; 52(6):1081-3. PubMed ID: 1661036 [No Abstract] [Full Text] [Related]
59. Complementary data about the inhibitory effects of intravenous immunoglobulins in vitro and in vivo. Casadei DH; Rial MC; Raimondi E; Goldberg J; Argento J; Haas E Transplantation; 1997 Apr; 63(8):1191-2. PubMed ID: 9133486 [No Abstract] [Full Text] [Related]